New eczema drug shows promise in Mid-Stage trial
NCT ID NCT07175233
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new injectable drug called SIM0278 for adults with moderate to severe atopic dermatitis (eczema) that needs systemic treatment. About 184 participants will receive either a low, medium, or high dose of SIM0278 or a placebo. The main goal is to see how much eczema symptoms improve after 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIM0278 injection
What this could lead to
If successful, this could lead to a new treatment option for people with moderate to severe eczema that is not well controlled by current therapies.
What could go wrong
This is an early Phase 2 trial with only 184 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hangzhou First People's Hospital, School of Medicine , West Lake University
Hangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
Shenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••